VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 355.5 EUR | +2.16% |
|
+1.86% | -1.11% |
| May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play |  |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated | |
| Sales 2024 * | 1.38B 1.48B | Sales 2025 * | 1.48B 1.59B | Capitalization | 2.98B 3.2B |
|---|---|---|---|---|---|
| Net income 2024 * | 139M 150M | Net income 2025 * | 155M 167M | EV / Sales 2024 * | 2.21 x |
| Net Debt 2024 * | 73.54M 79.14M | Net cash position 2025 * | 44M 47.35M | EV / Sales 2025 * | 1.98 x |
| P/E ratio 2024 * |
21.5
x | P/E ratio 2025 * |
19.4
x | Employees | 5,459 |
| Yield 2024 * |
0.41% | Yield 2025 * |
0.46% | Free-Float | 49.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Virbac
More press releases
More news
| 1 day | +2.16% | ||
| 1 week | +1.86% | ||
| Current month | +2.45% | ||
| 1 month | +1.86% | ||
| 3 months | +8.05% | ||
| 6 months | +27.88% | ||
| Current year | -1.11% |
1 week
343.00
356.00
1 month
342.00377.50
Current year
316.50377.50
1 year
232.50377.50
3 years
215.00448.50
5 years
132.20448.50
10 years
102.10448.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 10-12-31 | |
Philippe Capron
BRD | Director/Board Member | 65 | 03-12-31 |
| Chairman | 59 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 355.5 | +2.16% | 2,247 |
| 24-05-02 | 348 | +0.29% | 2,017 |
| 24-04-30 | 347 | -0.57% | 2,225 |
| 24-04-29 | 349 | 0.00% | 2,972 |
| 24-04-26 | 349 | +0.72% | 7,198 |
Real-time Euronext Paris, May 03, 2024 at 11:35 am EDT
More quotes
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
355.5
EUR
Average target price
368
EUR
Spread / Average Target
+3.52%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.11% | 3.21B | |
| -9.19% | 6.67B | |
| +24.75% | 3.7B | |
| +6.08% | 1.52B | |
| -15.13% | 1.37B | |
| -25.63% | 1.24B | |
| -7.62% | 1.21B | |
| -10.84% | 1.17B | |
| -.--% | 1.05B | |
| -7.07% | 832M |
- Stock Market
- Equities
- VIRP Stock
